Novo Nordisk to present Wegovy and next‑generation obesity data at ECO 2026

Conference overview

Novo Nordisk will present 52 abstracts at the European Congress on Obesity (ECO), 12–15 May in Istanbul, covering clinical trials and real‑world evidence for semaglutide‑based treatments and the investigational CagriSema combination.

Substances and trials

Data span oral semaglutide 25 mg (OASIS 4, ORION, OPTIC), injectable semaglutide (1.7 mg, 2.4 mg, 7.2 mg; STEP UP, SELECT), and CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg; REDEFINE), plus the OUTSTEP 1 real‑world study.

Clinical and real‑world endpoints

Presentations address early responder analyses, time to weight‑loss thresholds and durability, body composition and proximal muscle strength, control of eating, physical function, menopausal symptom associations (including interactions with menopausal hormone therapy), cardiovascular risk metrics including MACE, antimigraine medication use, and patient preferences for obesity medications.

Selected findings to be presented

Highlights include post‑hoc analyses on semaglutide 7.2 mg and oral 25 mg showing speed and durability of weight loss in early responders, STEP UP and REDEFINE dose–response and body‑composition results, and REDEFINE findings on predicted atherosclerotic cardiovascular disease risk reductions.

Regulatory status

FDA has approved Wegovy injections (1.7, 2.4, 7.2 mg) and the oral 25 mg tablet; EMA has approved injections (2.4, 7.2 mg) while the oral pill is pending review.